Evidence map›Paper›PMID 26636741›Full record

ArticleTransplantation2016

HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.

Shehnaz K Hussain, Solomon B Makgoeng, Matthew J Everly, Marc T Goodman, Otoniel Martínez-Maza, Lindsay M Morton, Christina A Clarke, Charles F Lynch, Jon Snyder, Ajay Israni and 2 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Cancer in kidney transplant recipients.Nature reviews. Nephrology · 2018
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 6 countries.

Shehnaz K Hussain1 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA. 3 Terasaki Foundation Laboratory, Los Angeles, CA. 4 Departments of Obstetrics and Gynecology and Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA. 5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 6 Cancer Prevention Institute of California, Fremont, CA. 7 Division of Epidemiology, Department of Health Research and Policy and Medicine, Stanford University School of Medicine, Stanford, CA. 8 Department of Epidemiology, University of Iowa, Iowa City, IA. 9 Scientific Registry of Transplant Recipients and Minneapolis Medical Research Foundation, Minneapolis, Minneapolis, MN.
Solomon B Makgoeng
Matthew J Everly
Marc T Goodman
Otoniel Martínez-Maza
Lindsay M Morton
Christina A Clarke
Charles F Lynch
Jon Snyder
Ajay Israni
Bertram L Kasiske
Eric A Engels
University of Iowa · USCancer Prevention Institute of California · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000824 · DP · TEXAS STATE DEPT OF HEALTH SERVICES · PI DELGADO, EVELYN · 2007 to 2011
$44.3M
NEW YORK STATE CANCER PREVENTION & CONTROL PROGRAMU58DP003879 · DP · NYSDOH/HEALTH RESEARCH, INC. · PI WALLACE, BARBARA J · 2012 to 2014
$37.6M
MICHIGAN CANCER PREVENTION & CONTROL PROGRAMU58DP003921 · DP · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI BROOKOVER, PATRICIA · 2012 to 2014
$30.7M
Category A - Communities Putting Prevention to WorkU58DP000848 · DP · COLORADO STATE DEPT/PUB HLTH & ENVIRONMT · PI JACOBELLIS, JILLIAN · 2007 to 2011
$25.9M
NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000832 · DP · NC STATE DEPT/HLTH & HUMAN SERVICES · PI PETERSEN, RUTH · 2007 to 2011
$23.6M
NATIONAL CANCER PREVENTION & CONTROL PROGRAM - ILLINOISU58DP003883 · DP · ILLINOIS STATE DEPT OF PUBLIC HEALTH · PI MOODY, CONNY · 2012 to 2014
$22.6M
CALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5M
GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMU58DP003875 · DP · GEORGIA DIVISION OF PUBLIC HEALTH · PI O'CONNOR, JEAN CATHERINE · 2012 to 2014
$15.9M
NEW JERSEY CANCER PREVENTION & CONTROL PROGRAMU58DP003931 · DP · NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS · PI RODRIQUEZ, GLORIA · 2012 to 2014
$11.9M
MASSACHUSETTS CANCER PREVENTION & CONTROL PROGRAMU58DP003920 · DP · MASSACHUSETTS STATE DEPT OF PUB HEALTH · PI NYAMBOSE, JOSHUA · 2012 to 2014
$11.4M
Molecular Epidemiology of B cell Activation, DNA Repair & HIV-Associated LymphomaK07CA140360 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUSSAIN, SHEHNAZ KHURSHEED · 2010 to 2014
$623k
CCR NIH HHS HHSN261201300011CNCCDPHP CDC HHS U58 DP000807NCCDPHP CDC HHS U58 DP000824NCCDPHP CDC HHS U58 DP000832NCCDPHP CDC HHS U58 DP000848NCCDPHP CDC HHS U58 DP003875NCCDPHP CDC HHS U58 DP003879NCCDPHP CDC HHS U58 DP003883NCCDPHP CDC HHS U58 DP003920NCCDPHP CDC HHS U58 DP003921NCCDPHP CDC HHS U58 DP003931NCI NIH HHS HHSN261201000024CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000036CNCI NIH HHS HHSN261201000037CNCI NIH HHS HHSN261201300011INCI NIH HHS HHSN261201300021CNCI NIH HHS HHSN261201300071CNCI NIH HHS K07 CA140360NCI NIH HHS N01 PC035137NCI NIH HHS N01 PC035139NCI NIH HHS N01 PC035142NCI NIH HHS N01 PC035143
6 · The paper itself

Abstract

backgroundSolid organ transplant recipients have heightened risk for diffuse large B cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established.

methodsWe examined 172 231 kidney, heart, pancreas, and lung recipients transplanted in the United States between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number.

resultsCompared with recipients who had 2 HLA-DR mismatches, those with zero or 1 mismatch had reduced DLBCL risk, (zero: IRR, 0.76, 95% confidence interval [95% CI], 0.61-0.95; one: IRR, 0.83; 95% CI, 0.69-1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all 3 loci (P = 0.0003). Several individual recipient HLA-A, -B, -C, -DR, and -DQ antigens were also associated with DLBCL risk, including DR13 (IRR, 0.74; 95% CI, 0.57-0.93) and B38 (IRR, 1.48; 95% CI, 1.10-1.93), confirming prior findings that these 2 antigens are associated with risk of infection-associated cancers.

conclusionsIn conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients or chronic immune stimulation.

Indexed as

Histocompatibility TestingAdultFemaleHLA AntigensHLA-DR AntigensHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOrgan TransplantationRiskHLA AntigensHLA-DR Antigens

Identifiers

PMID26636741
PMCPMC4893345
OpenAlexW2313748438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.